

Amendments to the Specification:

Please insert the following heading and paragraph on the first page of the specification after the title and before the BACKGROUND OF THE INVENTION:

--CROSS REFERENCE TO RELATED APPLICATIONS

This is a continuation of United States patent application Serial No. 10/142, 110, filed May 9, 2002, which is divisional of United States patent application Serial No. 09/443,061 filed November 18, 1999, now U.S. Patent No. 6,403,096, which is a divisional application of Serial No. 08/806,121, filed December 23, 1996 now U. S. Patent No. 6,008,319, which are all incorporated herein by reference.--

Please replace the paragraph beginning at page 8, line 19, with the following rewritten paragraph:

--Fig. 1 (A) shows the amino acid (SEQ ID NO:1) and DNA sequence (SEQ ID NO:2) of PEP (aa22-58 of full length IL-2), Fig. 1(B) shows a schematic drawing of IL-2 where helices are shown as cylinders (McKay, D.B., (1992)), Fig. 1(C) shows a stereogram of a C α atom backbone trace of one IL-2 molecule (McKay, D.B., (1992)), Fig. 1 (D) shows a ribbon diagram of a member of the right-handed cylinder family of predicted IL-2 structure (Cohen et al., (1986)), wherein the PEP sequence is highlighted and the disulfide bond is shown in Figs. 1(B), 1(C), and 1(D);--

Please replace the paragraph beginning at page 10, line 14, with the following rewritten paragraph:

--The length of the PEP is preferably at least about 22 amino acids in length and most preferably about 37 amino acids in length. Preferred embodiments of the peptide include amino acids residue numbers 37 to 58, 33 to 58, or 37 to 72 of amino acid sequence SEQ ID NO:13. These preferred embodiments exhibit about 50% of the vasopermeability effects of an IL-2 immunoconjugate when joined to an appropriate delivery vehicle. The most preferred embodiment of PEP comprises residue numbers 22 to 58 (SEQ ID NO:3), i.e., the entire amino acid sequence of SEQ ID NO:1. This PEP embodiment exhibits an optimum of about 100% of

the vasopermeability of an IL-2 immunoconjugate, when joined to an appropriate delivery vehicle.--

Please replace the paragraph beginning at page 32, line 18, with the following rewritten paragraph:

--From the data presented in Table 1, it appears that the entire sequence of amino acids 22-58 of SEQ ID NO:3 produces optimal vasopermeability. However, conjugates composed of amino acids 37-58, 33-58, and 37-72 of SEQ ID NO:3 retain 50% of the activity, whereas fragment E6, consisting of amino acids 22-38 of SEQ ID NO:3, has no activity.--